R. Cheney, M.D., Ph.D. 9/9 Seminar in TX

[Guest guest]

" Chronic Fatigue Syndrome: The Heart of the Matter "

a seminar by R. Cheney, M.D., Ph.D.

September 9th, 2006

2 pm - 5 pm

University of North Texas Health Science Center

(was known as TCOM)

3500 Camp Bowie Blvd

Fort Worth, TX

http://www.hsc.unt.edu/campusmap/printmap.htm

Everett Hall, rm 100, Research & Education Bldg.

During his three-hour presentation, Dr. Cheney will discuss his

latest

research and treatment findings. These include (but are not limited

to):

**Diastolic Dysfunction in CFS

Due to a lack of energy at the cellular level the hearts of CFS

patients

don't fill properly with blood; this is further complicated when

patients stand. Ninety-nine percent of Dr. Cheney's CFS patients

test

positive for diastolic dysfunction via echocardiograms (sonograms of

the

heart).

**Patent Foramen Ovales in CFS

A PFO is a flap-valve that allows blood to flow between the two

upper

chambers of the heart. Present in babies before they are born, it

usually seals shut after birth but remains in up to 20% of normal

adults

in whom it can open under certain rare conditions. PFO's are

unusually

common in CFS, with up to 80% of patients testing positive. The

presence

of a PFO in CFS can be very problematic. The underlying reason for

the

increase in PFO's in CFS may be the underlying energy deficits at

the

cellular level. Dr. Cheney believes that PFO closure in CFS poses

certain risks and there are indications that his treatment protocol

may

make such a procedure unnecessary for most patients.=20

**Therapeutic Responses to Cellular Energy Therapy as Measured by

Echocardiography

Dr. Cheney's current research treatment protocol is designed to

increase

cellular energy production by restoring the function of energy

systems

inside cells. The pre-treatment phase of the study improves certain

enzyme functions that are necessary for the safe production of

energy.

The pre-treatment phase also protects vital organs and modulates the

immune system. One way Dr. Cheney is measuring the effectiveness of

the

treatment protocol is by doing sonograms of the heart before and

after

the treatment.

**Oxygen therapy in CFS

Oxygen appears to be a blessing and a curse, depending upon the

dose.

Low dose oxygen appears to improve cardiac function, which has been

demonstrated by echocardiographic parameters sensitive to cellular

energetics. However, higher doses of oxygen appear to cause

significant

toxicity to the heart in general and to the main pumping chamber in

particular. This unusual sensitivity to oxygen toxicity appears

related

to the nature of the underlying defects responsible for reduced

cellular

energy.

*This event is sponsored by the CFS/FM Support Group of Dallas -

Fort

Worth.

www.dfwcfids.org

Questions - Email: carol@...